NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals said yesterday that it has closed its previously announced strategic alliance with Roche under which Roche agreed to license an Alnylam RNAi therapeutic technology platform and certain intellectual property, acquire one of Alnylam’s labs, and work with the firm on drug-discovery projects.
Under the agreement, Roche will make aggregate payments to Alnylam of around $331 million, including an upfront cash payment within ten business days of the closing in connection with the license.
In addition, the Roche Venture Fund has purchased 1.975 million shares of Alnylam common stock for a total of $42.5 million.
Roche also closed the purchase of an Alnylam lab in Kulmbach, Germany, for an undisclosed sum.
GenomeWeb Daily News sister publication RNAi News reported last month that Alnylam will have to pay around $30 million to other partners, primarily Isis Pharmaceuticals, from which it has licensed IP covered under the Roche deal.